Vera Therapeutics, Inc.
No SEC Form 4 filings for $VERA in the last 30 days.
See all $VERA insider activity →Vera Therapeutics (VERA) will present final efficacy data from the ORIGIN 3 trial of Trutakna (atacicept) for IgA nephropathy at the American Society of Nephrology's Kidney Week 2026. Trutakna is FDA-approved and targets a specific mechanism of action in the disease.
Vera Therapeutics (VERA) fell 7.23% after Leerink initiated coverage with a Market Perform rating, citing overly optimistic expectations for Trutakna's market share and peak sales. Leerink set a $34 price target, suggesting limited upside. Vera has no commercial revenue, increasing risks if Trutakna's demand is slower than expected.
Alignment Healthcare (ALHC) shares dropped 24.2% to $6.60 in pre-market trading after its largest California contract was downgraded to 3.5 stars, making it ineligible for bonus payments. Several other stocks also fell, including Entera Bio (ENTX), AT&T (T), Verizon (VZ), and RenX Enterprises (RENX).
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VERA (Vera Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent VERA coverage spans financial news, technology and market movers.
Upcoming trial data could move the stock depending on results.
Analyst downgrade pressure likely to keep the stock under pressure.
Small‑cap biotech sees modest sell‑off.
No material news; the piece is generic commentary without new data.
Potential dilution from employee equity awards.
AlphAI scores every news story that mentions VERA with an AI model for sentiment and relevance, and aggregates insider trades from Vera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vera Therapeutics (VERA) will present final efficacy data from the ORIGIN 3 trial of Trutakna (atacicept) for IgA nephropathy at the American Society of Nephrology's Kidney Week 2026. Trutakna is FDA-approved and targets a specific mechanism of action in the disease.
1 min readVera Therapeutics (VERA) fell 7.23% after Leerink initiated coverage with a Market Perform rating, citing overly optimistic expectations for Trutakna's market share and peak sales. Leerink set a $34 price target, suggesting limited upside. Vera has no commercial revenue, increasing risks if Trutakna's demand is slower than expected.
2 min readAlignment Healthcare (ALHC) shares dropped 24.2% to $6.60 in pre-market trading after its largest California contract was downgraded to 3.5 stars, making it ineligible for bonus payments. Several other stocks also fell, including Entera Bio (ENTX), AT&T (T), Verizon (VZ), and RenX Enterprises (RENX).
2 min readSimply Wall St analyzes Vera Therapeutics (VERA), highlighting key rewards and risks for investors. The article encourages independent research and provides tools for evaluating the company's financial health. It also mentions other investment opportunities in dividends, AI, and robotics.
1 min readVera Therapeutics (VERA) granted stock options and RSUs to five new employees on September 29, 2026. The options cover 16,700 shares at a $32.38 exercise price, and RSUs cover 8,350 shares. Both vest over four years, subject to continued service.
1 min readVera Therapeutics (VERA) reported positive final trial results for TRUTAKNA, meeting all endpoints in the ORIGIN 3 trial for IgA nephropathy. The data showed strong kidney function preservation and safety comparable to placebo. The company plans to use the data for a supplemental BLA filing in late 2026, which could expand TRUTAKNA's label. Vera Therapeutics currently has no meaningful revenue and a net loss of $401.9M, with a share price down 33% year-to-date.
2 min readVera Therapeutics (VERA) shares rose after the company reported final Phase 3 data showing its kidney drug TRUTAKNA reduced disease progression risk by 76% and stabilized kidney function. The results support a planned FDA filing for late 2026, with strong early launch metrics and heavy options trading. However, the company has no product revenue, rising losses, and cash burn, requiring successful sales and potential capital raising to sustain operations.
2 min readVera Therapeutics reported that TRUTAKNA met all endpoints in the Phase III ORIGIN 3 trial for IgA nephropathy, with strong kidney function data and a safety profile comparable to placebo. The company plans to seek full FDA approval in late 2026. According to the company, TRUTAKNA's self-administered format and early commercial momentum indicate a focus on real-world adoption. The therapy's potential as a disease-modifying treatment could reshape Vera's investment narrative, though the company r
3 min readFordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $37.00 ($0.68M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readVicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min read
